Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124152772 | 12415277 | 2 | F | 201601 | 20160627 | 20160530 | 20160725 | PER | US-PFIZER INC-2016247785 | PFIZER | 61.00 | YR | F | Y | 92.53000 | KG | 20160725 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124152772 | 12415277 | 1 | PS | NEURONTIN | GABAPENTIN | 1 | Oral | 100 MG, 1X/DAY | Y | 20235 | 100 | MG | CAPSULE, HARD | QD | |||||
| 124152772 | 12415277 | 2 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 600 MG, 3X/DAY | Y | 20235 | 600 | MG | CAPSULE, HARD | TID | |||||
| 124152772 | 12415277 | 3 | SS | NEURONTIN | GABAPENTIN | 1 | Oral | 300 MG, 3X/DAY | Y | 20235 | 300 | MG | CAPSULE, HARD | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124152772 | 12415277 | 1 | Neuropathy peripheral |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124152772 | 12415277 | Drug ineffective for unapproved indication | |
| 124152772 | 12415277 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124152772 | 12415277 | 2 | 2015 | 0 | ||
| 124152772 | 12415277 | 3 | 201601 | 201602 | 0 |